Navigation Links
Avanafil Data Presented at the European Society of Sexual Medicine Meeting
Date:12/5/2011

tudied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012.  For more information about the company, please visit www.vivus.com

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," predict," "opportunity" and "should," among others.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI ≥30 kg/m2), or overweight patients (BMI ≥27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our respo
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
2. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
5. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
8. New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
9. New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
10. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... STXS ) announced today the appointment of ... (EMEA) to lead the Company,s EMEA operations and sales ... utilization of its Niobe® Remote Magnetic Navigation System and ... P. Kaminski, President and CEO of Stereotaxis. ...
... Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial ... For the third quarter of 2010, the Company reported net income ... loss of $8.2 million, or $0.21 per share, for the same ... the Company reported a net loss of $10.5 million, or $0.20 ...
Cached Medicine Technology:Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 2Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 3Neurocrine Biosciences Reports Third Quarter 2010 Results 2Neurocrine Biosciences Reports Third Quarter 2010 Results 3Neurocrine Biosciences Reports Third Quarter 2010 Results 4Neurocrine Biosciences Reports Third Quarter 2010 Results 5Neurocrine Biosciences Reports Third Quarter 2010 Results 6Neurocrine Biosciences Reports Third Quarter 2010 Results 7Neurocrine Biosciences Reports Third Quarter 2010 Results 8
(Date:7/31/2014)... Seattle, WA (PRWEB) July 31, 2014 ... summer, Duke’s Chowder House is featuring new ... available at all six Duke’s locations throughout ... and out-of-town guests alike, Duke’s award-winning, customer-nominated Seattle’s best ... outdoor decks. To celebrate its Lake Union location’s 25th ...
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... California (PRWEB) July 31, 2014 Serious ... Dead Psychedelic Acid Test concert posters. Owsley Bear Stanley, ... logo for the Grateful Dead. According to Hawley, “The ... to promote acid test parties in San Francisco and ... were printed on three different colors of paper. They ...
(Date:7/31/2014)... over the age of 65 face numerous barriers to ... against poverty and higher rates of asthma with worse ... of Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), outlines the challenges faced by ... to improve their care. , "Allergists want ...
(Date:7/31/2014)... 1, 2014) If you have asthma, you may have ... help you recognize and respond to changes and understand when ... in the green zone, you,re doing well, yellow means your ... you require urgent care. New guidelines are now available to ... back into green and away from the red zone. , ...
Breaking Medicine News(10 mins):Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3
... at work are more likely than long hours, night ... interfere with their sleep. , That,s the conclusion of ... the annual meeting of the Population Association of America. ... approximately 2,300 U.S. adults that monitored the same workers ...
... Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through ... According to a New Report from Decision Resources, ... one of the,world,s leading research and advisory firms ... therapy,s overall clinical efficacy,(defined as cure or improvement ...
... Bionovo Inc.,(Nasdaq: BNVI ) announced today the appointment ... Directors. Dr. Baxter has extensive experience in,academic research as ... in advancing endocrine drugs., "We are very excited ... our,clinical trial programs," said Isaac Cohen, O.M.D., Bionovo,s Chairman ...
... April 17 Eisai Corporation of,North America today ... President of U.S. Corporate Communications. In this newly ... and coordinating,all of Eisai,s corporate communications strategies and ... to Eisai more than 22 years of global ...
... BERKELEY, Calif., April 17 Losing your home to,foreclosure ... loved one. And with so,many Americans facing this dreaded ... in default, according to USA TODAY (Nov. 11,2007) -- ... as,the financial and practical ones., In her seminal ...
... a life,sciences company based in Shanghai, China and ... made several executive management appointments to,build out its ... has joined ProGenTech as its Vice President for ... the global R&D programs,and have accountability for the ...
Cached Medicine News:Health News:U-M study: Work hassles hamper sleep 2Health News:Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia 2Health News:John D. Baxter, M.D. Joins Bionovo's Board of Directors 2Health News:John D. Baxter, M.D. Joins Bionovo's Board of Directors 3Health News:Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications 2Health News:Nolo.com Adds Up the Emotional Costs of Foreclosure With the Five Stages of Foreclosure Grief 2Health News:Nolo.com Adds Up the Emotional Costs of Foreclosure With the Five Stages of Foreclosure Grief 3Health News:ProGenTech Limited Appoints Executive Management Team 2
Inquire...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Medicine Products: